UNICEF has signed a supply agreement with Pfizer for the procurement of up to 4 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir (PAXLOVID™) in 2022.
UNICEF procurement of nirmatrelvir/ritonavir (PAXLOVID™) is dependent on country demand, clinical recommendations and necessary approvals.
In December 2021, the US Food and Drug Administration issued an Emergency Use Authorization for the use of nirmatrelvir/ritonavir (PAXLOVID™) for the treatment of mild to moderate cases of COVID-19. Nirmatrelvir/ritonavir (PAXLOVID™) is currently under assessment by the World Health Organization (WHO).